Analysts

Lennar Toll Brothers

Analysts Keefe, Bruyette & Woods upgraded Toll Brothers (TOL) to outperform with a target price of $161, while downgrading Lennar (LEN) to underperform with a target price of $86

Keefe, Bruyette & Woods has downgraded Lennar while upgrading Toll Brothers, reflecting a K-shaped recovery in the housing market that favors affluent buyers over entry-level consumers. This divergence highlights the contrasting outlooks for these two homebuilders amid ongoing economic pressures.

Zealand Pharma (ZEAL) Shares Plunge 23% Following Safety Concerns Over Survodutide Data

06/08/2026, 07:35 PM business stock_drop healthcare
Zealand Pharma's shares fell sharply by 22.7% following concerns over the safety profile of its weight loss drug survodutide, which showed a high dropout rate due to gastrointestinal side effects in a late-stage study. This decline highlights the challenges the company faces in a competitive market dominated by established players like Novo Nordisk and Eli Lilly.